학술논문
Effectiveness of Low Dose Ara-C in Acute Nonlymphocytic Leukemia and Myelodysplastic Syndromes —Analysis of foctors influencing on Duration of Responses, Survivals and Clinical Effects— / 急性非リンパ性白血病，MDSに対するAra-C少量療法の有効性
Document Type
Journal Article
Author
Harue HARUYAMA; Haruto UCHINO; Hideo HAYASHI; Hiromi YASHIGE; Hiromu NAKAYAMA; Hiromu OKADA; Hiromu TAZAWA; Hiroo FURUKAWA; Hiroshi FUJII; Hiroto ISHIKURA; Hiroyoshi SAWADA; Katsuhiko FUJIMORI; Keiko HODOHARA; Kiyoshi AKASAKA; Masafumi TANIWAKI; Masaro TAJIMA; Masataka SASADA; Mitsuhiko KOYA; Morihisa YAMAGISHI; Naohisa FUJITA; Shinobu NAKANISHI; Tadao USUI; Takayuki TAKAHASHI; Tatsuo ABE; Toshihiro MOCHIZUKI; Toshiro OKAZAKI; Yasuhiko INAMOTO; Yataro YOSHIDA; Yoichiro IZUMI; Yoshihide FUJIYAMA; Yoshiki KATOH; 中山 弘; 中西 忍; 内野 治人; 加藤 嘉樹; 古川 裕夫; 吉田 弥太郎; 和泉 洋一郎; 小屋 美津彦; 山岸 司久; 岡崎 俊朗; 岡田 弘; 彌重 博巳; 春山 春枝; 望月 敏弘; 林 英夫; 澤田 博義; 田嶌 政郎; 田澤 熙; 石倉 浩人; 程原 佳子; 稲本 康彦; 笹田 昌孝; 臼井 忠雄; 藤井 浩; 藤山 佳秀; 藤森 克彦; 藤田 直久; 谷脇 雅史; 赤坂 清司; 阿部 達生; 高橋 隆幸
Source
臨床血液 / Rinsho Ketsueki. 1987, 28(9):1553
Subject
Language
Japanese
ISSN
0485-1439
1882-0824
1882-0824
Abstract
Twenty six patients with acute nonlymphocytic leukemia (ANLL), 12 patients with myelodysplastic syndromes (MDS), none of whom received intensive chemotherapy, and 17 patients with relapsed and/or refractory ANLL were treated with low dose Ara-C therapy (LDAC) (10mg/m2/12hr S.G.). In cases who received no intensive chemotherapy, 15 patients with ANLL and 2 patients with MDS obtained complete remission (CR) and a patient with ANLL and 6 patients with MDS obtained partial remission. In refractory and/or relapsed ANLL cases only 4 patients obtained CR and a patient obtained PR. Patients with M1 and M2 achieved high response rates compared with M3, M5 and M6. In ANLL who received no intensive chemotherapy there was no apparent correlation between response and bone marrow cellularity, percentage or number of blasts in bone marrow. Duration of responses with ANLL without previous intensive chemotherapy, relapsed and/or refractory ANLL and MDS were from 3M to 17M (median 8M), from 13M to 42M (median 23M) and from 2M to 12M (median 6M) respectively. The median survival for all cases and responders was 16M and 22M in ANLL without previous intensive chemotherapy. 4M, 23M in relapsed and/or refractory ANLL and 31M and 31M in MDS. Present results show that treatment with low dose Ara-C may be effective in fresh ANLL patients with advanced age, hypoplastic bone marrow and/or peripheral cytopenia or severe complications. However further investigation is necessary to evaluate whether the therapy prolong the survival in MDS.